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Abstract
The ultrasound (US) features of breast cancer have recently been shown to have prognostic significance. We aim to assess 
these features according to molecular subtype. 1140 consecutive US visible invasive breast cancers had US size and mean 
stiffness by shearwave elastography (SWE) recorded prospectively. Skin thickening (> 2.5 mm) overlying the cancer on US 
and the presence of posterior echo enhancement were assessed retrospectively while blinded to outcomes. Cancers were clas-
sified as luminal, triple negative (TN) or HER2 + ve based on immunohistochemistry and florescent in-situ hybridization. The 
relationship between US parameters and breast cancer specific survival (BCSS) was ascertained using Kaplan–Meier survival 
curves and ROC analysis. At median follow-up 6.3 year, there were 117 breast cancer (10%) and 132 non-breast deaths (12%). 
US size was significantly associated with BCSS all groups (area under the curve (AUC) 0.74 in luminal cancers, 0.64 for TN 
and 0.65 for HER2 + ve cancers). US skin thickening was associated most strongly with poor prognosis in TN cancers (53% 
vs. 80% 6 year survival, p = 0.0004). Posterior echo enhancement was associated with a poor BCSS in TN cancers (63% 
vs. 82% 6 year survival, p = 0.02). Mean stiffness at SWE was prognostic in the luminal and HER2 positive groups (AUC 
0.69 and 0.63, respectively). In the subgroup of patients with TN cancers receiving neo-adjuvant chemotherapy posterior 
enhancement and skin thickening were not associated with response. US skin thickening is a poor prognostic indicator is all 
3 subtypes studied, while posterior enhancement was associated with poor outcome in TN cancers
Keywords Breast cancer · Ultrasound · Molecular subtype · Prognosis · Shear wave elastography
Introduction
Patients with invasive breast cancer are increasing likely to 
receive neoadjuvant systemic therapy than in previous years 
[1]. As such patients do not receive immediate surgery, the 
surgical specimen which has usually been used for prognos-
tic, assessment [2] is not available. The only histological 
information available is from the core biopsy sample. As a 
consequence, traditional prognostic information is not avail-
able in many women currently presenting with breast cancer.
However, recent work has highlighted prognostic indi-
cators which are available pre-operatively in almost all 
patients. A number of the ultrasound (US) features of breast 
cancer have recently been shown to indicate a poor outcome. 
These include large tumour size [3], skin thickening at the 
tumour site and posterior echo enhancement [4]. Skin thick-
ening on US and distance of the tumour from the skin have 
also previously been shown to correlate with the presence of 
nodal metastases and axillary nodal burden in those women 
undergoing immediate axillary clearance. Posterior echo 
enhancement has previously been shown to correlate with 
high histological grade and triple negative disease. Peri-
lesion stiffness on shear wave elastography (SWE) which 
is an ultrasound technique has recently been shown to be 
an independently associated with breast cancer death. Stiff-
ness at elastography is thought to represent abnormal col-
lagen structure in activated peri-tumoural stroma [5, 6]. Skin 
thickening and peri-lesional stiffness have previously been 
shown to have good intra-observer reproducibility [7, 8]. 
 * Andy Evans 
 A.Z.Evans@dundee.ac.uk
1 Mail Box 4 Ninewells Medical School, University 
of Dundee, Dundee DD1 9SY, USA
2 Breast Unit, Ninewells Hospital, Dundee DD1 9SY, USA




The reproducibility of classifying the presence or absence 
posterior echo enhancement is unknown.
The differing prognosis and response to neoadjuvant 
chemotherapy of the different molecular subtypes of breast 
cancer is well known and well reported [9]. Clinically useful 
prognostic indicators for women with luminal node negative 
cancers include a number of commercially available plat-
forms including Oncotype DX [10]. Such tests are, however, 
expensive and time consuming. However, similar tests are 
not available for triple negative cancers as putative mark-
ers such as androgen receptor and stromal tumour infiltrat-
ing lymphocytes (TIL’s) have either not gained widespread 
acceptance or have produced conflicting results [11, 12].
As US is performed on nearly all breast cancer patients 
and images are easily reviewed, any prognostic information 
derived from these images could be freely and readily avail-
able. The aim of this study is, therefore, to assess, in differ-
ent molecular subtypes, the value of established prognostic 
ultrasound (US) features of breast cancer.
Materials and methods
The study was carried out in a single breast unit which sees 
patients with symptoms and those with abnormal screening 
mammography.
US lesion size, mean stiffness of the cancer (kPa) at SWE 
and immunohistochemical data (Oestrogen receptor (ER), 
Progesterone receptor (PR), and HER-2 status) were col-
lected prospectively from a consecutive series of patients 
undergoing diagnostic breast US examination for lesions 
subsequently shown to be invasive breast cancer (n = 1141). 
These patients presented between April 2010 and September 
2015. Patients diagnosed with metastatic disease at pres-
entation were excluded. US lesion size measured both the 
hypoechoic and centre and the hyperechoic halo.
Patients were included irrespective of subsequent treat-
ment (primary surgery, neoadjuvant systemic therapy and 
primary endocrine therapy). All US scans were performed 
by one of six operators trained to perform and interpret 
breast ultrasound using a 12 MHz probe. These practition-
ers had between 7 and 22 years of breast ultrasound experi-
ence and had at least 12 months of experience performing 
breast SWE. Four SWE images in two orthogonal planes 
were obtained. A 2 mm region of interest (ROI) was used. 
Mean stiffness in kPa was taken as the average of the values 
taken from four SWE images. The maximum US diameter 
used in the analysis was the largest obtained in any of the 
three planes. All scans were performed using an Aixplorer® 
ultrasound system (SuperSonic Imagine, Aix en Provence, 
France).
The presence of overlying skin thickening (> 2.5 mm) at 
US (Fig. 1) and the presence of posterior echo enhancement 
(Fig. 2) (features recently found to be prognostic in women 
with invasive breast cancer) were assessed retrospectively 
while blinded to outcomes. The skin thickening cutoff of 
2.5 mm was decided upon, because normal breast skin meas-
ures up to 2 mm so a 2.5 mm cutoff would avoid diagnosing 
women with skin thickening who were at the upper border 
of the normal range. Patient’s survival including cause of 
death was ascertained from local paper and electronic health 
records. Patients that died after developing metastatic breast 
cancer were assumed to have died of breast cancer.
Cases were classified as luminal, triple negative (TN) 
and HER2 + ve on the basis of immunohistochemistry and 
florescent in-situ hybridization. Ki67 was not routinely avail-
able so splitting the luminal group into A and B was not 
Fig. 1  Ultrasound image of a triple negative breast cancer showing 
thickening of the overlying skin as indicated by the callipers
Fig. 2  Ultrasound image of a triple negative breast cancer showing 
posterior echo enhancement as shown by the arrow heads
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possible. Patients who were HER-2 positive and ER positive 
were included in the HER-2 positive group. Core biopsy 
estimated histological grade is given rather than final his-
tological grade as this can be used in all patients, however, 
treated. Cause and date of death were ascertained from local 
electronic databases.
The reproducibility of categorisation of US posterior echo 
enhancement was performed on a subset of 154 patients in 
whom two radiologists independently classified the presence 
or absence of posterior echo enhancement.
A sub-analysis of the TN cancers who underwent neo-
adjuvant chemotherapy (NACT) was performed to assess 
associations between responses to NACT as measured by 
residual cancer burden (RCB) scores and those US features 
found to be prognostic.
Statistical analysis was performed using Med  Calc® 
(MedCalc Software Ltd., Ostend, Belgium).
.The relationship between US parameters and breast 
cancer specific survival (BCSS) was ascertained using 
Kaplan–Meier survival curves and ROC analysis for the 
three subgroups. The difference between Kaplan–Meier 
curves was assessed using the log-rank test and the differ-
ence between ROC curves was assessed using the DeLong 
method. Agreement on the presence of posterior echo 
enhancement was assessed using Kappa statistics.
Results
1141 patients constituted the study group (mean age 
62.7 years, median age 62.6 years and range 24–95 years). 
433 (38%) patients had their cancer diagnosed at mammo-
graphic screening, while 708 (62%) women had sympto-
matic cancers. Mean follow-up in those alive was 6.3 years. 
During follow-up 117 breast cancer and 134 non-breast can-
cer deaths occurred.
The number of cancers and breast cancer deaths in each 
group were; luminal n = 857 (75%) and 54 (6%), TN n = 143 
(12.7%) and 36 (25%), and HER2 + ve n = 141(12.3%) and 
27 (20%). The pathological details and systemic therapy 
given of the entire cohort and subgroups are shown in 
Table 1. Invasive size and nodal status is only given for 
those treated with immediate surgery. Micro-metastases 
and isolated tumour cells were counted as node negative. 
The frequency of categorical variables by subtype were: 
posterior enhancement, TN 41%, HER2 + ve 21% and lumi-
nal 11%. Skin thickening TN % 25%, HER2 + ve21% and 
luminal 12%. Mean US size and stiffness for TN, HER2 + ve 
and luminal subtypes were 22 mm, 22 mm and 16 mm and 
137 kPa, 141 kPa and 126 kPa, respectively.
The relationship between BCSS and US features in sub-
groups are summarised in Tables 2 and 3 including hazard 
ratios (HR) and 95% confidence intervals (CI) for categori-
cal variables.
US size was significantly associated with BCSS in all 
groups but most strongly in luminal cancers (AUC 0.74, 
p < 0.001 compared to 0.64, p = 0.008 for TN and 0.65, 
p = 0.005 for HER2 + ve cancers). US skin thickening was 
also poorly prognostic in all groups but most strongly in 
TN cancers (53% vs. 80% 6 year survival, p = 0.0004, HR 
4.45 (95% CI’s 1.9–10.0), Fig. 3) and less so for HER2 + ve 
(66% vs. 83% 6 year survival, p = 0.04, HR 2.3 (95% CI’s 
1.1–5.0)) and luminal cancers (80% vs. 95% 6 year survival 
p < 0.0001, HR 23.6 (95% CI’s 9.1–61.3).
Table 1  Pathological and treatment details of the subgroups
Pathological feature Whole cohort number (%) Luminal number (%) HER2 positive number (%) Triple negative 
number (%)
Core biopsy estimated Histological grade 1 139 (12%) 136(16%) 2(1%) 1(1%)
Core biopsy estimated Histological grade 2 622(55%) 555(65%) 44(31%) 23(16%)
Core biopsy estimated Histological grade 3 380(33%) 166(19%) 95(67%) 119(83%)
Node positive 248 of 893 (28%) 189 of 715 (26%) 37 of 89 (42%) 22 of 89 (25%)
Invasive size > 20 mm 367 of 899 (40%) 271 of 718 (38%) 48 of 88 (55%) 48 of 93 (52%)
Neoadjuvant chemotherapy 120(10%) 31(4%) 42(30%) 47(33%)
Neoadjuvant/adjuvant chemotherapy 366(32%) 186(22%) 92(65%) 88(62%)
Adjuvant or neoadjuvant endocrine therapy 911(80%) 811(95%) 100(71%) 0
Total in each subgroup 1141 857(75%) 141(12%) 143(13%)
Table 2  Association between continuous US features and breast can-
cer specific survival in women by breast cancer subtype
US feature Subtype AUC and (95% CIs) p value
US size Triple negative 0.64 (0.56–0.72) 0.008
HER-2 positive 0.65 (0.56–0.73) 0.005
Luminal 0.74 (0.71–0.77)  < 0.001
Stiffness at SWE Triple negative 0.55 (0.47–0.63) 0.8
HER-2 positive 0.63 (0.55–0.71) 0.02
Luminal 0.69 (0.64–0.70)  < 0.001
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Posterior echo enhancement was associated with a poor 
BCSS in TN cancers (63% vs. 82% 6 year survival, p = 0.02, 
HR 2.2 (95% CI’s 1.11–4.31)) (Fig.  4). Posterior echo 
enhancement was not associated with a poor BCSS in lumi-
nal and HER2 + ve cancers (93% vs. 95% 6 year survival, 
p = 0.84 and 78% vs. 88% 6 year survival, p = 0.2, respec-
tively). The assessment of a subset of 154 patients regarding 
the presence or absence of posterior echo enhancement by 
two independent radiologists showed substantial agreement 
(Kappa statistic 0.66, 95% CI 0.53–0.79).
Mean stiffness at SWE was prognostic in the luminal 
group (6 year survival for soft vs stiff tumours was 97% vs. 
89%, p = 0.0002, area under ROC curve 0.69, p < 0.001). 
Mean stiffness at SWE was prognostic in the HER2 + ve 
patients when continuous data was analysed (area under 
ROC curve 0.63, p = 0.02) but not in triple negative patients 
(68% vs. 80% 6 year survival, p = 0.15, respectively, area 
under ROC curve 0.55, p = 0.8).
The sub-analysis of patients with TN cancers who under-
went NACT (n = 47) showed a strong relationship between 
RCB score and survival (area under ROC curve 0.74, 
p = 0.002). No relationship was seen between RCB score 
and either US skin thickening or posterior echo enhance-
ment (area under ROC curve 0.52, p = 0.8 and 0.52. p = 0.8).
Discussion
We have found associations between the US features of 
breast cancer and BCSS in all three main molecular sub-
groups of breast cancer. However, the individual features 
which are significant and the strength of such associations 
vary by molecular subtype. In TN breast cancer US detected 
skin thickening and posterior echo enhancement have strong 
associations with poorer outcome. In luminal cancers US 
size, skin thickening and stiffness at SWE appear most use-
ful. In HER2 positive cancer significant but less striking 
associations are found with US size, skin thickening and 
stiffness at SWE.
Women with TN breast cancer have very varied out-
comes but few clinically useful prognostic indictors. Basal 
Table 3  Association between categorical US features and breast can-
cer specific survival in women by breast cancer subtype
US feature Subtype Hazard ratio (95% CIs) p value
Skin thickening Triple negative 4.45 (1.9–10.0)  < 0.001
HER-2 positive 2.3 (1.1–5.0) 0.04
Luminal 23.6 (9.1–61.3)  < 0.001
Posterior echo 
enhancement
Triple negative 2.2 (1.11–4.31) 0.02
HER-2 positive 0.55 (0.22–1.39) 0.2
Luminal 1.1(0.45–2.63) 0.84
Comparison of survival curves (Logrank test) 
Chi-squared 12.6678
DF 1
Significance       P = 0.0004
Hazard ratiosa with 95% Confidence Interval 
Factor no skin thickening skin thickening
no skin thickening - 4.35261.9364 to 9.7837
skin thickening 0.22970.1022 to 0.5164 - 
a Column/Row 
Fig. 3  Kaplan–Meier survival curves (in years) for triple negative 
breast cancers according to the presence of skin thickening
Comparison of survival curves (Logrank test) 
Chi-squared 5.2048
DF 1
Significance       P = 0.0225
Hazard ratiosa with 95% Confidence Interval 
Factor enhancement no enhancement
enhancement - 0.45490.2312 to 0.8950
no enhancement 2.19851.1174 to 4.3256 - 
a Column/Row 
Fig. 4  Kaplan–Meier survival curves (in years) for triple negative 




phenotype cancers, which are often triple negative show lit-
tle relationship between tumour size, nodal stage and out-
come [13, 14]. Women with TN breast cancer are, therefore, 
a group where US prognostic indicators would be useful.
Skin thickening on US is usually not apparent clinically. 
In a previous study the vast majority of breast cancer deaths 
occurring in women with US skin thickening occurred in 
women without clinical evidence of skin involvement [4]. 
We do not have clinical examination findings in the patients 
in this study. However, only 23% of patients in this study 
who had US skin thickening received NACT. NACT has 
been the treatment of choice for clinical inflammatory can-
cers during the study period. It is, therefore, likely that the 
vast majority of patients in this study with US skin thicken-
ing did not have clinically inflammatory breast cancer.
The poor BCSS associated with US thickening appears to 
be related to the presence of a florid vascular and lymphatic 
plexus beneath the skin. The presence of lymphovascular 
invasion (VI), which is most frequently seen in a sub-dermal 
location, is a recognised prognostic factor in breast cancer 
[15, 16]. A number of previous studies have shown that a 
small tumour-to-skin distance is associated with lymph node 
metastasis in breast cancer [17, 18]. Why skin thickening has 
particular prognostic significance in TN breast cancers is not 
clear. We found no relationship between skin thickening and 
response to NACT so the mechanism would appear not to be 
related to sensitivity to chemotherapy.
It is known that posterior echo enhancement is found 
more frequently in high grade cancers, as many TNBCs are 
[19]. It has been claimed that cancers which show posterior 
echo enhancement are more cellular and have less desmopla-
sia than those cancers not showing posterior echo enhance-
ment [20, 21]. The association between poor BCSS in TN 
cancers with posterior echo enhancement is not a function 
of histological grade as virtually all TN cancers are grade 
3. Neither does the presence of posterior echo enhancement 
appear to be related to sensitivity to chemotherapy as we 
found no relationship between posterior echo enhancement 
and response in those TN cancers who were treated with 
NACT. The cause of the relationship between posterior echo 
enhancement and BCSS in TN cancer is unlikely to be solely 
due to necrosis. Necrotic tumours will tend have posterior 
echo enhancement due to the excellent transmission of US 
through fluid but necrosis occurs centrally, while poste-
rior echo enhancement is seen behind the whole tumour. 
Necrosis has been found to be a poor prognostic factor in 
TN breast cancer [22].
The lack of an association between stiffness at SWE and 
outcome in TN cancers suggests that the mechanical proper-
ties of abnormal collagen structure and organisation are less 
important in TN cancers than in luminal cancers, where the 
association between stiffness and BCSS is strong. Recent 
previous studies have confirmed the good reproducibility of 
stiffness measured at SWE and US assessment of skin thick-
ening [7, 8]. In this study we have also found assessment of 
posterior echo enhancement to be reliable with agreement 
between two independent radiologists in 85% of cases. The 
US features associated with outcome in breast cancer patients 
appear, therefore, to show good reproducibility and, therefore, 
promise in terms of clinical usefulness.
It should, however, be noted that other stromal markers of 
outcome such as TIL’s are associated with outcome in TN 
breast cancer [11]. Further research is needed on the correla-
tion between TIL’s and US features.
The weaknesses of this study include that it is from a sin-
gle centre and that some of the factors evaluated such as skin 
thickening and posterior echo enhancement were assessed 
retrospectively, albeit on images that had been prospectively 
collected and saved. While the overall number of cases and 
breast cancer deaths are large, the numbers in subgroups are 
more modest. The mean follow-up of 6.3 years means that a 
significant number of breast cancer deaths which will occur 
in this cohort have not yet happened, this will be particularly 
true in the luminal subgroup. However, the data for TN and 
HER2 + does have follow-up beyond the initial 5 years during 
which many events will occur.
The factors of definitive tumour grade and nodal status have 
not included in the analysis as these are only known with cer-
tainty post operatively. In contrast, US features are available 
for analysis in the preoperative setting.
In summary, we have found associations between the US 
features of breast cancer and BCSS in all the molecular sub-
groups of breast cancer but the associations vary according 
to subtype. In TN breast cancer US detected skin thickening 
and posterior echo enhancement have strong associations with 
poor outcome.
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